FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:94-96 January 5, 2006 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Abraham, E. PubMed Citation

To the Editor: In the article by Abraham et al. (Sept. 29 issue),¹ the ADDRESS (Administration of Drotrecogin Alfa [Activated] in Early Stage Severe Sepsis) trial showed no benefit of drotrecogin alfa (activated) (DrotAA) in patients with severe sepsis and a low risk of death (defined by single-organ failure or an Acute Physiology and Chronic Health Evaluation [APACHE II] score <25).² In contrast to the prematurely terminated PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial,³ the ADDRESS study showed higher mortality in its subgroup of patients treated with DrotAA who had an APACHE II score of . . . [Full Text of this Article]

This article has been cited by other articles:

• Marshall, J. C. (2008). Sepsis: rethinking the approach to clinical research. J. Leukoc. Biol. 83: 471-482 [Abstract] [Full Text]